Liu Yingna, Baker Olesya, Schuur Jeremiah D, Weiner Scott G
Duke University School of Medicine, Durham, North Carolina, USA.
Brigham and Women's Hospital, Boston, Massachusetts, USA.
Pain Med. 2020 Sep 1;21(9):1863-1870. doi: 10.1093/pm/pnz210.
We quantified opioid prescribing after the 2014 rescheduling of hydrocodone from schedule III to II in the United States using a state-wide prescription database and studied trends three years before and after the policy change, focusing on certain specialties.
We used Ohio's state prescription drug monitoring program database, which includes all filled schedule II and III prescriptions regardless of payer or pharmacy, to conduct an interrupted time series analysis of the nine most prescribed opioids: hydrocodone, oxycodone, tramadol, codeine, and others. We analyzed hydrocodone prescribing trends for the physician specialties of internal medicine, anesthesiology, and emergency medicine. We evaluated trends 37 months before and after the rescheduling change.
Rescheduling was associated with a hydrocodone level change of -26,358 (95% confidence interval [CI] = -36,700 to -16,016) prescriptions (-5.8%) and an additional decrease in prescriptions of -1,568 (95% CI = -2,296 to -839) per month (-0.8%). Codeine prescribing temporarily increased, at a level change of 6,304 (95% CI = 3,003 to 9,606) prescriptions (18.5%), indicating a substitution effect. Hydrocodone prescriptions by specialty were associated with a level change of -805 (95% CI = -1,280 to -330) prescriptions (-8.5%) for anesthesiologists and a level change of -14,619 (95% CI = -23,710 to -5,528) prescriptions (-10.2%) for internists. There was no effect on prescriptions by emergency physicians.
The 2014 federal rescheduling of hydrocodone was associated with declines in hydrocodone prescriptions in Ohio beyond what had already been occurring, and hydrocodone may have been briefly substituted with codeine. These results indicate that rescheduling did have a lasting effect but affected prescribing specialties variably.
我们利用一个全州范围的处方数据库,对2014年美国将氢可酮从III类重新划分为II类药物后的阿片类药物处方情况进行了量化,并研究了政策变化前后三年的趋势,重点关注某些专科领域。
我们使用俄亥俄州的州处方药监测计划数据库,该数据库包括所有已配药的II类和III类处方,无论付款人或药房如何,对九种最常开具的阿片类药物(氢可酮、羟考酮、曲马多、可待因等)进行中断时间序列分析。我们分析了内科、麻醉科和急诊科医生开具氢可酮的趋势。我们评估了重新分类变更前后37个月的趋势。
重新分类与氢可酮处方量变化-26358张(95%置信区间[CI]=-36700至-16016)(-5.8%)相关,且每月处方量额外减少-1568张(95%CI=-2296至-839)(-0.8%)。可待因的处方量暂时增加,处方量变化为6304张(95%CI=3003至9606)(18.5%),表明存在替代效应。各专科开具的氢可酮处方量变化方面,麻醉科医生为-805张(95%CI=-1280至-330)(-8.5%),内科医生为-14619张(95%CI=-23710至-5528)(-10.2%)。对急诊科医生的处方量没有影响。
2014年联邦政府对氢可酮的重新分类与俄亥俄州氢可酮处方量的下降有关,且下降幅度超过了原本已经出现的下降幅度,氢可酮可能曾被可待因短暂替代。这些结果表明重新分类确实产生了持久影响,但对各专科的处方情况影响各异。